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Abstract
Background: Staphylococcus aureus is implicated in many opportunistic bacterial infections around the world. Rising
antibiotic resistance and few alternative methods of treatment are just two looming problems associated with clinical
management of S. aureus. Among numerous virulence factors produced by S. aureus, staphylococcal enterotoxin (SE) B is a
secreted protein that binds T-cell receptor and major histocompatibility complex class II, potentially causing toxic shock
mediated by pathological activation of T cells. Recombinant monoclonal antibodies that target SEB and block receptor
interactions can be of therapeutic value.
Methodology/Principal Findings: The inhibitory and biophysical properties of ten human monoclonal antibodies, isolated
from a recombinant library by panning against SEB vaccine (STEBVax), were examined as bivalent Fabs and native full-length
IgG (Mab). The best performing Fabs had binding affinities equal to polyclonal IgG, low nanomolar IC50s against SEB in cell
culture assays, and protected mice from SEB-induced toxic shock. The orthologous staphylococcal proteins, SEC1 and SEC2,
as well as streptococcal pyrogenic exotoxin C were recognized by several Fabs. Four Fabs against SEB, with the lowest IC50s,
were converted into native full-length Mabs. Although SEB-binding kinetics were identical between each Fab and respective
Mab, a 250-fold greater inhibition of SEB-induced T-cell activation was observed with two Mabs.
Conclusions/Significance: Results suggest that these human monoclonal antibodies possess high affinity, target specificity,
and toxin neutralization qualities essential for any therapeutic agent.
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Introduction
Staphylococcus aureus is a common source of many diseases for
both humans and domestic animals [1]. This bacterium presents a
daunting medical problem due to increasing antibiotic resistance
among nosocomial- and community-acquired isolates [2–4]. The
economic burden of S. aureus upon healthcare systems around the
world is substantial and new means of controlling diseases caused
by this pathogen are clearly needed now [5,6].
To gain an infective foothold, S. aureus produces several factors
that facilitate adherence, interfere with a proper immune response,
or otherwise alter the host microenvironment. One type of
virulence factor includes the staphylococcal enterotoxins (SEs),
originally distinguished by serotyping methodology [7–10]. These
protein toxins can cause acute gastroenteritis and toxic shock
syndrome. Although SEs (.20 known to date) appear distinct by
amino acid sequence comparisons [11], all share common
superantigen structures consisting of an N-terminal OB (oligonu-
cleotide/oligosaccharide binding) fold and C-terminal, ubiquitin-
like, beta-grasp domain. Related superantigenic proteins are also
expressed by another bacterial pathogen, Streptococcus pyogenes [12].
SE cross-linking of major histocompatibility complex class II
molecules (MHC II) and specific subsets of T-cell antigen receptors
(TCR) activate the immune system [13]. Superantigenic effects
[14] involve profound T-cell proliferation and elevated levels of
the proinflammatory cytokines interferon gamma (IFNc), inter-
leukin 2 (IL-2), and tumor necrosis factor alpha (TNFa). Toxic
shock syndrome, due to bacterial superantigen exposure, can
rapidly progress to severe and intractable hypotension, multi-
system failure and death.
Concerning toxin-induced diseases associated with S. aureus, the
most comprehensive clinical data are available for staphylococcal
toxic shock caused by toxic shock syndrome toxin-1 (TSST-1).
There is a clear predisposition towards initial and recurring bouts
of toxic shock syndrome among menstruating women lacking pre-
existing antibodies against TSST-1 [15,16]. Significant levels of
TSST-1 antibodies are found amongst approximately 85% of
menstruating women between 13 and 40 years of age [16]. In
particular, TSST-1 specific IgG1 and IgG4 are protective whereas
IgM and IgA reportedly have no effect [15]. Non-menstrual toxic
shock, which can be more deadly than menstrual forms [17], has
been linked to SEB, TSST-1, and other bacterial superantigens
produced by S. aureus [18]. Experimentally, antibodies against
superantigens can be neutralizing and induced by recombinant
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to naı ¨ve mice or non-human primates concomitant to, or hours
after, toxin exposure protect against toxic shock [24–26].
While concentrated preparations of non-specific human immu-
noglobulin (i.e. intravenous immunoglobulin or IVIg) are used to
treat streptococcal- and staphylococcal-induced shock, clinical
trials are rather limited to date [27,28]. Preparations of these
polyclonal antibodies from humans neutralize superantigens in vitro
[29,30], although other non-specific mechanisms may contribute
to protection [31]. Reports also suggest that some IVIg
preparations are simply not efficacious for streptococcal and
staphylococcal infections [32–34]. Additionally, the IVIg used
clinically may be more effective towards streptococcal than
staphylococcal superantigens, and there is also a natural batch-
to-batch variation [35,36]. A step beyond IVIg involves clinical
trials targeting a few select antigens from S. aureus through: 1)
immunization of humans and subsequent collection of immuno-
globulins; or 2) recombinant generation of antibodies. However,
these more-targeted approaches are either currently being tested
or have failed to perform [28].
Clearly, there is a need for well-characterized, safe and
efficacious immunotherapeutics for treating diseases linked to
staphylococcal superantigens like SEB. Recombinant human
monoclonal antibodies can be manufactured under controlled
conditions and are potential alternatives to IVIg. It is possible to
select or engineer native-like monoclonal antibodies with almost
any specificity by harnessing recombinant DNA technologies [37].
Furthermore, recipients are less prone to a life-threatening
anaphylactic reaction [38] or anti-therapeutic antibody response,
possible consequences of giving any foreign immunoglobulin to
humans.
We selected human monoclonal antibodies from a phage-
display library, using a recombinant SEB vaccine (STEBVax)
incorporating site-specific mutations that prevent MHC II
interactions [21]. Previous studies show that antibody responses
to STEBVax protect rhesus macaques against toxic shock caused
by wild-type SEB [21,22]. In this current study, we discovered that
some antibody clones cross-react with SEC1, SEC2, and
streptococcal pyrogenic exotoxin C (SpeC), while others were
highly specific for SEB. Many of the antibodies effectively
inhibited T-cell activation by SEB in vitro, bound to toxin with
nanomolar affinity, and prevented SEB-induced toxic shock in vivo.
Results
Antibody Specificity
Previous studies showed that rhesus macaques vaccinated with
STEBVax, an SEB molecule containing MHC II-binding site
mutations (L45R, Y89A, and Y94A), produced antibodies that
prevented SEB-induced illness [20–22]. Reasoning that neutral-
izing antibodies could be obtained without requiring biocontain-
ment facilities, we used STEBVax to pan the synthetic phage-
display library and select recombinant human antibodies [39].
The probe antigen was biotinylated and bound to paramagnetic
beads covalently modified with streptavidin to enable selection of
antibodies in solution. Ten human Fabs thus selected were initially
tested for reactivity with other bacterial superantigens by ELISA
(Table 1). All STEBVax-panned Fabs, except #4, recognized
wild-type SEB. Seven of the antibodies also recognized closely-
related SEC1 and/or SEC2 [40], and five cross-reacted with
SpeC, a pattern also exhibited by SEB affinity-purified IgG from
human sera (Table 1). None of the antibodies reacted with SEA,
TSST-1, or SpeA as measured by ELISA.
In addition to staphylococcal and streptococcal toxin recogni-
tion of Fabs by ELISA, Western blots were done with S. aureus
culture fluid and cell lysate (Fig. 1). Eight of the ten Fabs
specifically recognized SEB in complex antigen preparations from
a previously characterized strain of S. aureus. Two Fabs did not
detect SEB under these conditions, including Fab 4 that yielded
similar results by ELISA. These two antibodies likely recognize
conformation-dependent epitopes. In addition to the 1 h
incubation of Fab with antigen (Fig. 1), there were similar,
specific-banding patterns after only a 15 min incubation of
primary antibody (data not shown).
Kinetic Analysis of Antibody Binding to SEB
Interactions between immobilized antibody and solution-phase
SEB were analyzed by SPR. Although all Fabs were tested, we
were able to obtain complete data for antibodies 1, 3, 6, 9, and 10
(Table 2). The SPR results confirmed specific binding for
antibodies 2, 4, 5, 7, and 8, but systematic deviation between
the experimental and fitted curves, based on 1:1 Langmuir
binding, prevented accurate calculations of association and
dissociation rates. Both Fab 10 and the affinity-purified polyclonal
antibody exhibited similar nanomolar KDs and binding kinetics
with no apparent correlation between antigen cross-reactivity
(Table 1) and SEB-binding affinity (Table 2). Select Fabs were
converted to full-length, native Mabs and the binding kinetics with
SEB examined again. Antibody interactions with SEB appeared
similar between each Fab and its native Mab derivative, suggesting
minimal disturbance of epitope recognition by Fc addition
(Table 2).
Antibody Inhibition of SEB Binding to MHC II
From a therapeutic perspective, it was important to ascertain if
any of the recombinant antibodies interfered with SEB binding to
receptor in a biological assay. Antibody-mediated inhibition of
Table 1. Specificity of Human Monoclonal Fabs for
Staphylococcal and Streptococcal Superantigens.
Antibodya Antigen
SEA SEB SEC1 SEC2 TSST-1 SpeA SpeC
1-
b +++ +++ -- --
2- ++++ -- - - -
3- ++++ -- - - +
4- - - + -- +
5- +++ -- - - -
6- ++++ ++++ + -- ++
7- +++ +++ -- --
8- +++ +++ -- --
9- ++ - + -- ++
10 - ++ + ++ -- ++
Polyclonal IgG - +++ ++ +++ -- ++
aNumbered antibodies are monoclonal Fabs. Polyclonal IgG is anti-SEB affinity
purified from human sera.
bScoring by ELISA:
-=,0.5 mean absorbance +/2 standard deviation.
+=0.5–1.0.
++=1.0–2.0.
+++=2.0–3.0
++++=3.0–4.0.
doi:10.1371/journal.pone.0013253.t001
Human Mabs to SEB
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examined antibody inhibition of SEB - MHC II interactions using
an LG2 cell-based assay and flow cytometry analysis (data not
shown). Only Fabs 9 and 10 effectively prevented SEB binding
(,95%) to MHC II, and these antibodies were equivalent in this
assay to the SEB-purified IgG from human sera used as a control.
Fab 1 weakly (,20%) inhibited SEB binding to MHC II while
Fabs 2 - 8 had no effect. There was no inhibition of SEB binding
to MHC II by a control Fab (SEA-selected clone). Furthermore,
direct comparison of parental Fabs with native-length Mabs 9 and
10 revealed no differences in blocking SEB binding to MHC II by
this assay.
Antibody Inhibition of T-cell Response to SEB
We next addressed toxin-neutralizing capabilities of the
antibodies in cell culture. Activation of T lymphocytes in human
mononuclear cell cultures was monitored by measuring release of
IFNc in response to SEB pre-incubated with each antibody. By
IC50 determination, the most potent (SEB-neutralizing) Fabs were
1, 3, 9 and 10, whereas Fabs 7 and 8 had no inhibitory effect
(Table 3). Although the positive antibody control (SEB-specific
IgG from human sera) effectively inhibited T-cell activation by
SEB, Fab 10 was slightly better. A negative control Fab against
SEA, which did not react with SEB by ELISA, had no effect upon
SEB-induced activation of T cells.
To further complement the SEB studies, we also examined Fab
inhibition of T-cell responses to other cross-reacting superantigens.
Fab 6 most effectively inhibited SEC1-induced responses, as
monitored by IFNc secretion, and was slightly more potent than
the polyclonal IgG (Table 3). Uniquely, the IC50 of Fab 6 against
SEC1 was approximately two-fold better than that for SEB.
Among the remaining cross-reacting antibodies, Fab 1 had a
barely-detectable effect against SEC1. Although six of the Fabs
recognized SpeC by ELISA (Table 1), only Fab 9 had any
significant effect on SpeC-induced stimulation of T-cells. In
contrast to the recombinant antibodies, polyclonal IgG more
effectively inhibited SpeC, versus SEB or SEC1, activation of
human T cells (Table 3). Altogether, these results indicated that
common, neutralizing epitopes on staphylococcal and streptococ-
cal superantigens are recognized by this panel of human
monoclonal antibodies.
The SPR-based results (Table 2) indicated that interactions with
SEB were similar between Fab and native-structured Mab.
Therefore, we next examined T-cell responses to see if the
antibody form influenced inhibition of SEB. Our results indicated
that the IC50s for native-length Mabs 1 and 3 were essentially the
same as the parental Fabs by cellular assay (Table 3). In sharp
contrast, the IC50s of Mabs 9 and 10 against SEB were
significantly (,250-fold) better than the parental Fab. However,
this effect was not apparent with SpeC. Further comparisons
revealed that Mabs 9 and 10 were respectively 65- and 280-fold
more potent than polyclonal IgG against SEB.
Upon establishing that select Fabs prevented superantigen-
induced stimulation of human T-cells when premixed with toxin,
we next examined delayed addition of antibody. Human PBMCs
were cultured with SEB (0.35 nM), and Fabs (1000 nM) were then
added to wells at designated time intervals (Fig. 2A). Preliminary
studies investigating IFNc release, following toxin stimulation of
PBMCs, revealed that IFNc is undetected in culture fluid until 7 h
after toxin addition. There is a subsequent linear increase in IFNc
concentrations that plateaus and remains stable between 22–48 h
after toxin exposure (data not shown). Inhibitory profiles could be
separated into Fabs that blocked IFNc release #5 h after SEB
addition, or Fabs inhibiting T-cell responses .5 h. Most
noteworthy, SEB-induced T-cell responses were inhibited 75%
by Fab 1 up to 12 h after SEB exposure (Fig. 2A), whereas
inhibition by the SEB affinity-purified IgG dropped to 0% by 12 h
(Fig. 2B). An SEA-specific, control Fab had no effect on T-cell
responses (Fig. 2B). The inhibition range of SEB Fabs at 1 h varied
from 30–100%, and by 3 h spanned 0–97% (Fig. 2A). Fab 4 was
slightly better than all others except Fab 1, inhibiting 50% of the
IFNc release at 5 h post-SEB.
In contrast to the results obtained with Fabs (Fig. 2A), the
native-length Mabs 3, 9, and 10 inhibited 60 – 80% of T-cell
responses up to 12 h after SEB (Fig. 2C). In a manner similar to
Fab 1, native Mab 1 was also inhibitory but to a lesser extent (60–
30%). Overall, these observations suggested that biological activity
of the Fabs was influenced by added Fc in this assay.
To examine the role of Fc receptors, mouse L-cells devoid of Fc
receptor were used to replace the mixed mononuclear cells in the
IFNc assay. The L cells were transfected with human MHC II
(HLA-DR1a/b) for presentation of SEB to human T-cells. Results
with the L-cell transfectants indicated that inhibition of SEB-
Figure 1. Antibody detection of SEB in a complex antigen
mixture by Western blot. A 10–20% gradient SDS-PAGE separated
crude S. aureus antigen preparations subsequently transferred onto
nitrocellulose. Each Fab (1 mg/ml) was used to probe the nitrocellulose
for 1 h. Lanes include: A- 50 ng purified SEB; B – 20 mg cell lysate; and C
–2 0mg culture supernatant.
doi:10.1371/journal.pone.0013253.g001
Human Mabs to SEB
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13253induced T-cell responses by native Mab returned to a level
equivalent to Fab, suggesting an important contribution of Fc
receptors towards toxin neutralization (data not shown).
Antibody Neutralization of SEB in Mice
To further study protective capabilities of select antibodies, we
used a mouse model of SEB-induced toxic shock (Table 4). The
results were compared to controls receiving SEB only (0%
survivors) or SEB plus anti-SEA Fab (17% survivors). Fab 10
and its full-length native construct both provided the highest
protection (68%) from toxic shock within the groups examined,
followed by Fab 1 (42%) and Fab 9 (34%). These results were
consistent with the IC50s of Fab 10, Fab 1, Fab 9 (Table 3). In
contrast, Fab 3 and Mab 9 were no different than controls given
anti-SEA Fab. While a more comprehensive study will be required
to differentiate the biological effects of each antibody in vivo, these
data are in general agreement with the collective in vitro results.
Discussion
Virulence factor-specific antibodies derived from vaccination or
employed as therapeutics represent a potential defense against
bacterial diseases. Our results describe for the first time
recombinantly-derived, human monoclonal antibodies against
SEB that possess high affinity, target specificity, and therapeutic
potential for superantigen-induced toxic shock. These antibodies
prevent intoxication by interfering with toxin binding to MHC II
and/or TCR. In addition to potential applications for treating
toxic shock syndrome, human monoclonal antibodies recognizing
SEB or other bacterial superantigens may be useful if employed as
an adjunct therapy with antibiotics in treating difficult S. aureus
infections. For example, a combination of antibiotics and
immunoglobulins was previously advocated for combating S.
pyogenes infections [41,42]. This paradigm may be effective against
methicillin-, as well as vancomycin-, resistant strains of S. aureus
[3,4,43,44] since many isolates in the United States produce
various superantigens that include SEB and SEC [27].
Other antibody-based therapeutic approaches have been
suggested for treating S. aureus infections. For example, a phase
II study employing a humanized IgG1 targeting S. aureus clumping
factor A (ClfA; a fibrinogen-binding protein) resulted in good
tolerance by patients and promising preliminary clinical findings
[45]. An IVIg preparation used clinically in neonates contains
antibodies against microbial surface components that recognize
Table 3. Antibody Inhibition of Human T-Cell Responses to
Bacterial Superantigens.
IC50 (nM).
Antibody
a SEB SEC1 SpeC
Fab 1 205 1487 nt
b
FL 1 100 nt nt
Fab 2 1255 nt nt
Fab 3 199 nt .1500 (3)
c
FL 3 241 nt nt
Fab 4 558 nt .1500 (0)
Fab 5 772 nt nt
Fab 6 875 480 nt
Fab 7 .1500 (6) .1500 (23) nt
Fab 8 .1500 (9) .1500 (20) nt
Fab 9 444 nt 769
FL 9 1.44 nt 916
Fab 10 77 nt .1500 (39)
FL 10 0.32 nt .1000 (0)
Anti-SEB
d 92 570 59
SEA Fab
e .1500 (0) nt nt
aFL = full-length native Mab. All data show antibody inhibition of toxin-
induced IFNc release, relative to toxin only-treated PBMCs that act as a control.
Data represent the mean of quadruplicate readings resulting from two
separate experiments.
bNot tested, due to weak cross-reactivity by ELISA.
cPercent inhibition given in parentheses at the highest concentration (1500 nM
for Fab and 1000 nM for FL Mab) of weak-performing antibodies.
dPolyclonal anti-SEB from human sera, affinity-purified against SEB.
eControl human Fab against SEA that did not cross-react with SEB by ELISA.
doi:10.1371/journal.pone.0013253.t003
Table 2. Kinetic Analysis of Immobilized Human Antibody Interactions with SEB in Solution.
Fab Native Full-Length Mab
Antibody
a ka (1/Ms) kd (1/s) KD (M) ka (1/Ms) kd (1/s) KD (M)
1 4.7610
3
(+/22.9610
2)
b
6.9610
23
(+/22.3610
24)
1.7610
26
(+/21.7610
27)
6.2610
3
(+/28.3610
2)
6.7610
23
(+/25.2610
24)
1.1610
26
(+/22.3610
27)
3 1.5610
4
(+/21.8610
2)
3.3610
24
(+/23.3610
26)
2.3610
28
(+/2 0)
5.0610
4
(+/22.6610
3)
3.7610
24
(+/25.7610
25)
7.5610
29
(+/27.4610
210)
6 96.9 (+/22.5) 4.1610
25
(+/24.2610
26)
4.2610
27
(+/24.4610
28)
nt
c nt nt
9 7.3610
3
(+/29.4610
2)
1.6610
24
(+/22.0610
25)
2.2610
28
(+/25.0610
211)
1.7610
4
(+/22.8610
3)
1.8610
24
(+/22.2610
25)
1.1610
28
(+/21.1610
29)
10 2.7610
4
(+/22.1610
3)
1.2610
24
(+/21.6610
25)
4.2610
29
(+/22.8610
210)
5.1610
4
(+/21.3610
4)
6.3610
25
(+/23.6610
26)
1.3610
29
(+/22.5610
210)
Polyclonal IgG nt nt nt 3.2610
5
(+/24.9610
3)
3.3610
24
(+/25.3610
25)
1.0610
29
(+/21.8610
210)
aAntibody immobilized on a CM5 chip with SEB used as analyte. Polyclonal IgG was SEB affinity-purified IgG from human sera.
bStandard deviation.
cNot tested.
doi:10.1371/journal.pone.0013253.t002
Human Mabs to SEB
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13253Figure 2. Therapeutic capabilities of antibodies added after SEB in human PBMC cultures. Fab or native full-length (FL) Mabs were used
at a final concentration of 1000 nM and added at designated times after SEB (0.35 nM). Culture fluids were collected 16 h after SEB addition and IFNc
concentrations ascertained as described in the Materials and Methods. Panels A and C respectively show Fab and FL-Mab results. Antibody controls
consisted of a SEA-specific Fab and SEB affinity-purified IgG from human sera (Panel B). Results are representative of two separate experiments.
doi:10.1371/journal.pone.0013253.g002
Human Mabs to SEB
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and Staphylococcus epidermidis [46]. In particular, fibrinogen binding
proteins ClfA and SDrG (S. epidermidis serine-aspartate repeat
protein G) are recognized by the IVIg. It is conceivable that a
combination of well-characterized human monoclonal antibodies
targeting S. aureus toxin(s) and surface antigens [28,47,48] may be a
more useful immunotherapeutic for treating S. aureus infections.
Furthermore, combinations of human anti-SEB monoclonal
antibodies may be more effective than one, as previously
demonstrated with monoclonal antibodies specific for Clostridium
botulinum neurotoxin A [49] and tetanus toxin [50]. The use of
SPR and different antibody combinations, or an ELISA with
labeled monoclonal antibody and unlabeled competitor, could
provide important insight into antibody combinations more useful
in neutralizing SEB in vivo versus a single antibody. However, our
studies showed that native Mabs 9 and 10 individually were more
effective inhibitors of SEB than affinity-purified, polyclonal anti-
SEB from human sera. A recent study by Tilahun et al.
characterizes chimeric (human-mouse) monoclonal antibodies
against SEB that are, like our findings with human monoclonal
antibodies, not cross-reactive with SEA or TSST-1 [51]. Two of
these chimeras recognize distinct epitopes, neutralize toxin in vitro
and in vivo, and have a neutralizing synergy when combined
against SEB in vitro.
In addition to in vitro characterization of the monoclonal
antibodies in our study, biological assays involving human cell
culture were used to predict the physiological (i.e. toxin
neutralizing) effects of each antibody. The Fc domains added to
Fabs 1 and 3 had minimal effects upon IC50s in cell culture,
whereas native full-length Mabs 9 and 10 resulted in much higher
inhibition versus their Fab counterparts. The increased efficacy of
native Mabs 9 and 10 appeared dependent upon Fc receptors on
mononuclear cells. Comparisons of any native full-length Mab
with parental Fab revealed no significant differences in SEB-
binding kinetics by SPR, and thus minimal disturbance of
paratopes. Uniquely, antibodies 9 and 10 were the only two that
significantly inhibited SEB binding to MHC II. Although it was
plausible that Fc addition to Fabs 9 and 10 increased steric
hindrance of toxin-TCR interactions, as reflected in the IC50
values, comparison of Fab with its native-length Mab revealed no
differences in blocking SEB binding to MHC II. Fab 10 or its
native Mab derivative were also the best performers in the mouse
assay, thus agreeing with the predicted IC50s from cell culture.
Additionally, mouse and non-human primate results from others
describe antibody protection from SEB-induced toxic shock up to
4 h after toxin exposure [25,26]. Such findings in vivo are
congruent with our study using human cell culture and application
of antibody after SEB. In fact, for one Fab (#1) there was
noticeable protection (75%) 12 h post-SEB that was better than
affinity-purified polyclonal antibody. Collectively, previous in vivo
studies and the current cell-based efforts suggest that human
monoclonal antibodies against SEB can act as potent neutralizers
of toxin post exposure.
In addition to SEB, target specificity of each antibody was
further examined with other staphylococcal and streptococcal
superantigens by ELISA. Particularly noticeable was that many of
the SEB-selected Fabs cross-reacted with SEC1 and/or SEC2.
Similar results were previously demonstrated with rabbit antisera
[9,52] and mouse monoclonal antibodies [7,53]. SEB shares the
highest sequence identity with SECs (68%), versus SEA (33%) or
TSST-1 (26%) [54,55]. Vaccination of mice with either SEB or
SEC1 protects against heterologous toxin, clearly suggesting
common, neutralizing epitopes recognized by antibodies [10,21].
Additionally, there was also significant cross-reactivity of Fabs 6,
9, and 10 with SpeC from S. pyogenes. However, this toxin shares
less sequence homology (21%) with SEB compared to the non-
reactive SpeA (52%). Perhaps the SpeC epitopes recognized by
Fabs 6, 9, and 10 are more conformationally similar to SEB
versus those on SpeA. Although ELISA cross-reactivity of the
SEB affinity-purified antibodies from human sera with SEC1 and
SpeC was equivalent, the IC50 was 10-fold higher for SEC1 versus
SpeC. Our results revealed no cross-reactivity of any human
monoclonal antibody or polyclonal SEB-specific IgG with SEA,
SpeA, or TSST-1. Furthermore, each monoclonal antibody was
also tested by Western blots using crude cell lysates and culture
fluid of a SEB-producing strain of S. aureus as target antigen.
There was high specificity of these antibodies (i.e. only one
immunoreactive band evident), with exceptions being Fabs 4 and
5 that were not reactive and thus likely targeting conformation-
ally-sensitive epitopes.
Immunoreactivity of at least one antibody was assay dependent
as evidenced by Fab 4 and recognition of STEBVax, but not wild-
type SEB, in an ELISA. This same antibody did not recognize
SEB by Western blot. The difference between SEB and STEBVax
consists of three residue changes which affect binding to MHC II.
It is possible that adsorption of wild-type SEB onto an ELISA well
distorted the epitope recognized by Fab 4, thus effectively
preventing antibody-antigen interactions. However, results from
IC50 and therapeutic experiments suggested that Fab 4 effectively
interacted with SEB in solution. Overall, such data suggest binding
differences among the tested antibodies and recognition of very
subtle differences in amino acid sequences and/or conformations
of SEB. Furthermore, the strategy of using a recombinantly-
attenuated molecule of SEB (STEBVax) is potentially useful for
other toxins in which there are concerns (biodefense or otherwise)
linked to shipping and biocontainment.
Finally, polyclonal antibodies from pooled human sera are
currently used to treat various diseases such as Kawasaki’s
syndrome, Clostridium difficile colitis, respiratory syncytial virus,
cytomegalovirus, chronic dysimmune neuropathies, chronic in-
flammatory demyelinating polyradiculo-neuropathy, and polyar-
teritis nodosa [56–62]. These IVIg products naturally vary in
batch-to-batch potency, represent a potential risk for transmitting
infectious agents, and the mechanisms of action are generally not
well characterized [31]. Recombinantly-engineered human mono-
clonal antibodies targeting specific virulence factors, as presented
in this current study, circumvent many of these concerns.
Table 4. Antibody Neutralization of SEB in vivo.
Antibody
a % Survival
b
Fab 1 42
Fab 3 17
Fab 9 34
FL 9 17
Fab 10 68
FL 10 68
SEA Fab
c 17
None 0
aFL = full-length native Mab.
bn=12 for Fab 1, SEA Fab, and None. n=6 for all other groups. Before
intraperitoneal injection of each mouse, antibody (10 mg) was premixed with
SEB (2.5 mg) for 30 min at 22uC. Survival was recorded over a 72 h period.
cControl human Fab against SEA and not cross-reacting with SEB by ELISA.
doi:10.1371/journal.pone.0013253.t004
Human Mabs to SEB
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Human Monoclonal Antibodies
SEB-specific antibodies were isolated from a phage-displayed,
recombinant antibody library (MorphoSys AG, Martinsried,
Germany) as described previously [39]. Briefly, each of the human
variable heavy (VH) and light (VL) chain subfamilies frequently
used during an immune response were represented by one
consensus framework, thus resulting in seven master genes each
for the VH and VL chains. Hypervariable genetic cassettes
encoding the complementarity-determining regions were intro-
duced into the framework sequences to create .1.2610
10 clones.
Each cDNA encoded a bivalent Fab (110 kDa) containing a 5 kDa
homodimerization domain (dHLX), fused to 6xHis and Myc tags
at the C-terminus of the heavy chain to facilitate subsequent
purification and detection. The panning antigen (STEBVax),
previously developed as a vaccine [20–22], was a recombinant
SEB harboring three site-specific mutations in residues comprising
the MHC II binding surface. For panning, STEBVax was
biotinylated and bound to streptavidin covalently attached to
paramagnetic beads. After enrichment of SEB-specific phage, the
antibody genes were subcloned as a pool into an E. coli expression
vector [39]. Proteins from the transformants were screened for
binding to SEB by ELISA, as described below. The concentration
of each antibody specific for SEB was assessed by absorbance at
280 nm (A280) using an extinction coefficient of 0.7 for 1 mg/ml,
and aliquots subsequently stored at 280uC. Endotoxin levels for
each antibody were ,1.5 units/ml as determined by a Limulus
amebocyte lysate assay (BioWhittaker, Walkersville, MD). Select
Fabs were converted into native full-length (FL) IgG (Mab)
expressed in HEK cells, using the above technology [39], and then
purified for additional study. Purity of the SEB-specific antibodies
was confirmed by SDS-PAGE and Coomassie Blue staining.
Polyclonal Human Anti-SEB Immunoglobulins
Polyclonal IgG, specific for SEB, was prepared from pooled
human sera [29,63]. Purified, wild-type SEB (Toxin Technology,
Sarasota, FL) was coupled to cyanogen bromide-activated
Sepharose 4B (Sigma Chemical Co., St. Louis, MO) and used as
an affinity matrix. Semi-purified human IgG from sera (FFF
Enterprises, Temecula, CA) was diluted to 1 mg/ml with
phosphate buffered saline, pH 7.4 (PBS) and then passed over
the SEB-containing column. After addition of semi-purified IgG,
the column was washed with PBS until the A280 readings returned
to baseline. SEB-specific IgG was eluted from the column with
0.1 M glycine buffer (pH 2.5) and dialyzed extensively against
PBS. Protein concentrations were determined by a bicinchoninic
acid assay (Pierce, Rockford, IL) with purified human IgG as a
standard. Purity of the SEB-specific IgG was confirmed by SDS-
PAGE and Coomassie Blue staining.
Antibody Cross-Reactivity
Cross-reactivity of each Fab was tested by ELISA with various
wild-type bacterialsuperantigens.Purified SEA, SEB, SEC1,SEC2,
TSST-1, streptococcal pyrogenic exotoxin A (SpeA), and SpeC
(Toxin Technology, Sarasota, FL) were each applied (5 mg/ml PBS)
in triplicate to Costar 96-well flat bottom plates (Corning Inc.,
Corning, NY) for 2 h at 37uC. PBS containing 0.1% bovine serum
albumin (BSA) was used as a negative control to establish baseline
data. Plates were blocked (16 h, 4uC) with 0.2% casein in PBS and
washed with PBS containing 0.05% Tween-20 using an ELx405
Select washer (BioTek Instruments, Winooski, VT). ELISA plate
wells were incubated (90 min, 37uC) with either Fab (2 mg/ml) or
the SEB affinity-purified IgG from human sera (20 mg/ml), diluted
in PBS containing 0.02% casein. Plates were washed and incubated
with goat anti-human F(ab)’2 – horseradish peroxidase conjugate
(90 min,37uC).Tetramethyl-benzidine substrate(Pierce) wasadded
to each well and absorbance (650 nm) recorded at 40 min. Wells
were scored positive if the mean absorbance +/2 standard
deviation of triplicates was greater than twice the baseline. Results
are representative of three separate experiments.
Western blots were done to test binding specificity of each Fab
using S. aureus lysate and culture supernatant as complex antigen
mixtures. Previously characterized S. aureus (strain 14458) was
grown overnight at 37uC in brain heart infusion broth [64].
Following centrifugation, protein from lysed cells (B-PER; Pierce)
and culture supernatant were precipitated overnight by cold
acetone (70%). The precipitate was centrifuged, protein pellet
gently washed with Tris-buffered saline (TBS), and finally
dissolved in TBS. Protein concentrations were determined by
the bicinchoninic acid assay (Pierce). Proteins were separated by
10–20% gradient SDS-PAGE and transferred onto a nitrocellulose
membrane (Invitrogen, Carlsbad, CA) that was then blocked
overnight in TBS – 0.1% Tween 20 (TBST) containing 3% BSA.
Each Fab (1 mg/ml in TBST) was then applied to the membrane
for 1 h at room temperature and the latter subsequently washed
(4615 min) with TBST. There was a subsequent 1:2000 dilution
of goat anti-human F(ab)’2– horseradish peroxidase conjugate
added to the membrane for 1 h at room temperature. Following
TBST washes, immunoreactive bands were detected by electro-
chemiluminescence (Pierce).
Kinetic Analysis of Toxin-Antibody Interactions
Interactions of antibodies with SEB were assessed by surface-
plasmon resonance (SPR) using a Biacore 3000 instrument
(Biacore Inc., Piscataway, NJ). Mouse anti-histidine tag (AbD
Serotec, Dusseldorf, Germany) or goat anti-human Fc (GE
Healthcare, Piscataway, NJ) antibodies were immobilized in
10 mM acetate buffer (pH 5.0) at high densities (8000 resonance
units or RUs) on a CM5 sensor chip. The SEB antibodies were
captured using increasing concentrations to reach an Rmax of
analyte optimal for kinetic analysis (50–250 RUs). To measure
association rates, dilutions of SEB (11–2700 nM) in 0.1 M HEPES
buffer containing 1.5 M NaCl, 30 mM EDTA, and 0.5% P40
surfactant (pH 7.4, 25uC) were used at a flow rate of 50 ml/min
(3 min total time). Running buffer (as above) was then injected
(50 ml/min for 5 min) to assess the dissociation phase. Surfaces
were regenerated using 10 mM glycine buffer (pH 1.8) or a 3M
MgCl2 solution injected at 30 ml/min for 30 sec. The resulting
sensorgrams were analyzed with BIAevaluation software to
determine the association (ka) and dissociation (kd) rate constants,
using a Langmuir 1:1 binding model. The dissociation constant
(KD) was calculated as kd/ka. Results are representative of two
separate experiments.
Antibody Inhibition of Toxin-induced Stimulation of
T-cells: IC50 and Therapeutic Potential in vitro
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-hypaque density separation (4606g for 30 min at 4uC) from
healthy human donors. The PBMC layer was removed, washed
three times in RPMI medium, and cryopreserved in 10%
dimethylsulfoxide plus 90% fetal calf serum (FCS) under liquid
nitrogen. For T-cell assays, cryopreserved PBMCs were rapidly
thawed (37uC water bath), gently washed twice in RPMI (37uC)
containing 10% FCS, and dispersed into 96-well plates (10
5cells/
well). To establish the 50% inhibition concentration (IC50) of each
antibody, cells were incubated (16 h, 37uC) in duplicate wells with
0.25–1500 nM antibody and concentrations of each toxin
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SEC1 (1.3 nM), or SpeC (467 nM). Negative and positive
antibody controls respectively consisted of an SEA-specific Fab
(not cross-reactive with SEB) and affinity-purified anti-SEB IgG
from human sera. Media were collected from the cultures and
released IFNc used as a marker of T-cell activation. To test
antibody blocking of SEB-induced stimulation of T cells after toxin
exposure (i.e. therapeutic potential), each monoclonal antibody
(1000 nM) was added to PBMCs at 1, 3, 5, 7, 9, or 12 h after SEB
(0.35 nM). Duplicate wells were pooled and tested for IFNc.
To measure cytokine levels, anti-human IFNc capture antibody
(Thermo Fisher, Waltham, MA), rabbit anti-SEA antibody
(negative control; Toxin Technology), and Alexa647-labeled
streptavidin (positive control; Invitrogen) were arrayed onto
PATH Protein Microarray slides (Gentel Bioscience, Madison,
WI) using an inkjet microarray spotter (ArrayJet, Roslin, Scotland,
UK). The microarrayed slides were blocked (2 h, 22uC) in 50 mM
HEPES buffer (pH 7.4) containing 200 mM NaCl, 0.08% Triton
X-100 and 50% glycerol. Culture supernatants diluted 1:3 in
sample buffer (1% BSA +0.1% Tween-20 in PBS) were incubated
on the surface of each slide (1.5 h, 22uC). Media from PBMC
cultures stimulated for 24 h with 2 mg/ml phytohemagglutinin
(Invitrogen) were calibrated against an IFNc standard (National
Cancer Institute, Frederick, MD) using a cytometric bead assay
(BD Biosciences, San Jose, CA). Following washes in 1% BSA
+2% Tween-20 in PBS, slides were incubated (1 h, 22uC) with
1 mg/ml of biotinylated anti-human IFNc (Invitrogen), washed
and developed (1 h, 22uC) with Alexa647-labeled streptavidin
(1 mg/ml). The microarrays were washed to remove non-bound
streptavidin, dried, and fluorescent binding events measured by a
GenePix 4000B. The IC50 was calculated relative to SEB-treated
PBMCs without antibody. The therapeutic potential of each
antibody was plotted as percent inhibition over time. Results are
representative of two experiments with separate donors.
Mouse L-cells were used to examine the role of Fc receptors in
toxin neutralization by native full-length Mabs. These cells, which
do not express endogenous Fc receptors, were transfected with the
genes for human MHC II proteins (HLA-DR1a/b) and used to
present SEB to T-cells as described elsewhere [65], and above.
Antibody Inhibition of SEB Binding to MHC II
The HLA-DR1 homozygous B lymphoblast line, LG2, was used
to detect antibodies that inhibited SEB - MHC II (HLA-DR, -DQ,
-DP) interactions. SEB (1 mM) was incubated (30 min, 37uC) with
antibodies (0.5–5 mM) in Dulbecco’s Modified Eagle’s Medium
(DMEM) before addition to cells in 96-well plates. The cells
(5610
5/well) were cultured (20 min, 37uC, 5% CO2) in DMEM
containing 10% FCS. Positive and negative controls included SEB
incubated with either affinity-purified anti-SEB IgG from human
sera or anti-SEA Fab (5 mM), respectively. Following a DMEM
wash (4uC), cells were incubated (30 min, 4uC) with a 1:50 dilution
of rabbit anti-SEB (Toxin Technologies). Additional washes in
DMEM were followed by a 1:25 dilution of goat anti-rabbit
antibody conjugated to fluorescein isothiocyanate (Pharminogen,
San Jose, CA). After a final wash, cells were fixed in 1%
paraformaldehyde and SEB binding was determined by flow
cytometry (FACSCalibur, Becton Dickinson, Mountain View,
CA). Percent inhibition was calculated by comparison of antibody-
treated cells incubated with SEB, but no monoclonal antibody,
and all other reagents (0% inhibition). Results are indicative of
three separate experiments.
Antibody Inhibition of Toxic Shock
Finally, antibodies were tested in vivo for SEB neutralization in a
toxic shock model involving synergy of bacterial superantigens
with lipopolysaccharide [23–25]. Each BALB/c mouse (20 g
females purchased from the National Cancer Institute, Frederick,
MD) was injected intraperitoneally with SEB (2.5 mg) previously
incubated for 30 min at 22uC with antibody (10 mg). Mice were
housed in a pathogen-free environment with food and water
supplied ad libitum. Survival was recorded 72 h after injection and
each test group consisted of six animals, unless stated otherwise.
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